Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Rapid Test Diagnoses Severe Sepsis

By LabMedica International staff writers
Posted on 04 Nov 2014
A rapid test has been developed that could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately. More...


The discovery of the test could cut back on the lengthy diagnostic time, which can take 24 to 48 hours usually required to confirm if a patient is suffering from sepsis and increase the odds that they will respond to treatment.

Scientists at the University of British Columbia (Vancouver, BC, Canada) recruited 72 total patients which proved subsequently to include 37 sepsis patients. The majority of patients, 83%, were enrolled from the emergency room. Blood was collected in EDTA tubes at the time of initial blood culture, and immediately placed on ice. Plasma and buffy coat were separated and two aliquots transferred into bar-coded cryovials at -20 °C until they were transferred to a -80 °C freezer.

Transcriptomic analysis was performed by the high throughput sequencing of complementary DNA (cDNAs) (ribonucleic acid sequencing, RNA-Seq) and cDNA libraries were prepared from total RNA using the TruSeq Stranded Total RNA Sample Prep Kit with Ribo-Zero sample preparation guide (Illumina; San Diego, CA, USA). RNA-Seq was performed on Illumina’s GAIIx instrument using a single read run of 63 bp-long sequence reads.

All patients who were suspected to have infection upon first clinical presentation were confirmed in 19 of the 37 individuals who were eventually diagnosed with sepsis. Nevertheless, similar levels of significance of association of the endotoxin tolerance signature with sepsis were observed for this group as a whole, and for that subset of the group with confirmed infections. Amongst those with sepsis, the Endotoxin Tolerance Signature was significantly enriched in the culture positive group, although there was a trend towards enrichment in the culture negative group.

The full 99 gene Endotoxin Tolerance Signature was useful for characterizing the immune dysfunction in sepsis, but a smaller number of genes would be of more use in a diagnostic test. The team selected genes that showed greater than 1.5-fold differential expression between sepsis patients and controls, and identified a core-set of 31 genes from the original 99 gene Endotoxin Tolerance Signature. The new test for the genetic signature takes as little as one hour and identified 96% of patients who were at the very early stages of sepsis.

Robert E.W. Hancock, PhD, a professor of microbiology and senior author of the study, said, “We identified a gene signature that is associated with the eventual diagnosis of sepsis and subsequent organ failure. We can test for this genetic signature as soon as the patient arrives in the emergency ward. With sepsis, every hour counts, the treatment involves aggressive antibiotics but the most potent drugs can't be administered until a diagnosis is confirmed because of the risk of antibiotic resistant bacteria.” The study was published on October 7, 2014, in the journal EbioMedicine.

Related Links:

University of British Columbia
Illumina 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.